on Fresenius SE & Co. KGaA (ETR:FRE)
Moody's Upgrades Fresenius' Outlook to Positive
Moody’s Ratings has shifted its credit outlook for Fresenius SE & Co. KGaA from stable to positive, affirming the company's Baa3 rating. The decision cites Fresenius’ improved growth trajectory and profitability, attributed to the #FutureFresenius strategy. Moody’s also noted the enhancement of Fresenius’ credit metrics and robust liquidity.
Sara Hennicken, Fresenius CFO, remarked on the improved financial profile, emphasizing the reduction in the net leverage ratio to 2.5x. The company aims to invest in innovation-driven growth, particularly in Medtech, Nutrition, and Biopharma sectors.
Fresenius continues to achieve significant organic revenue and EPS growth. Key investments include acquiring 45% of mAbxience and collaborating with WuXi Biologics to expand its biosimilars pipeline.
All leading credit rating agencies have now rated Fresenius with a positive outlook. The firm remains committed to maintaining investment grade ratings and a leverage target range of 2.5-3.0x net debt/EBITDA.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Fresenius SE & Co. KGaA news